FI109123B - Analogiamenetelmä 5-lipoksigenaasi-inhibiittoreina käyttökelpoisten 4-aryyli-4-hydroksi-tetrahydropyraanien ja 3-aryyli-3-hydroksi-tetrahydrofuraanien valmistamiseksi - Google Patents

Analogiamenetelmä 5-lipoksigenaasi-inhibiittoreina käyttökelpoisten 4-aryyli-4-hydroksi-tetrahydropyraanien ja 3-aryyli-3-hydroksi-tetrahydrofuraanien valmistamiseksi Download PDF

Info

Publication number
FI109123B
FI109123B FI955165A FI955165A FI109123B FI 109123 B FI109123 B FI 109123B FI 955165 A FI955165 A FI 955165A FI 955165 A FI955165 A FI 955165A FI 109123 B FI109123 B FI 109123B
Authority
FI
Finland
Prior art keywords
methyl
oxo
hydroxy
tetrahydroquinolin
group
Prior art date
Application number
FI955165A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI955165A (fi
FI955165A0 (fi
Inventor
Thomas Geoffrey Colerick Bird
Michael Stewart Large
Graham Charles Crawley
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of FI955165A publication Critical patent/FI955165A/fi
Publication of FI955165A0 publication Critical patent/FI955165A0/fi
Application granted granted Critical
Publication of FI109123B publication Critical patent/FI109123B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
FI955165A 1993-04-29 1995-10-27 Analogiamenetelmä 5-lipoksigenaasi-inhibiittoreina käyttökelpoisten 4-aryyli-4-hydroksi-tetrahydropyraanien ja 3-aryyli-3-hydroksi-tetrahydrofuraanien valmistamiseksi FI109123B (fi)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP93401120 1993-04-29
EP93401120 1993-04-29
EP93401991 1993-08-02
EP93401991 1993-08-02
EP94400190 1994-01-28
EP94400190 1994-01-28
PCT/EP1994/001277 WO1994025453A1 (en) 1993-04-29 1994-04-25 4-aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors
EP9401277 1994-04-25

Publications (3)

Publication Number Publication Date
FI955165A FI955165A (fi) 1995-10-27
FI955165A0 FI955165A0 (fi) 1995-10-27
FI109123B true FI109123B (fi) 2002-05-31

Family

ID=27235558

Family Applications (2)

Application Number Title Priority Date Filing Date
FI955165A FI109123B (fi) 1993-04-29 1995-10-27 Analogiamenetelmä 5-lipoksigenaasi-inhibiittoreina käyttökelpoisten 4-aryyli-4-hydroksi-tetrahydropyraanien ja 3-aryyli-3-hydroksi-tetrahydrofuraanien valmistamiseksi
FI20020270A FI20020270A (fi) 1993-04-29 2002-02-11 4-aryyli-4-hydroksi-tetrahydropyraanit ja 3-aryyli-3--hydroksi-tetrahydrofuraanit 5-lipoksygenaasi-inhibiittoreina

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20020270A FI20020270A (fi) 1993-04-29 2002-02-11 4-aryyli-4-hydroksi-tetrahydropyraanit ja 3-aryyli-3--hydroksi-tetrahydrofuraanit 5-lipoksygenaasi-inhibiittoreina

Country Status (24)

Country Link
US (2) US5478842A (es)
EP (1) EP0623614B1 (es)
JP (1) JP3553127B2 (es)
KR (1) KR100358464B1 (es)
CN (1) CN1052002C (es)
AP (1) AP9400632A0 (es)
AT (1) ATE163417T1 (es)
AU (1) AU681886B2 (es)
CA (1) CA2121199C (es)
CZ (1) CZ280695A3 (es)
DE (1) DE69408593T2 (es)
DK (1) DK0623614T3 (es)
ES (1) ES2112483T3 (es)
FI (2) FI109123B (es)
GB (1) GB9408001D0 (es)
HK (1) HK1004777A1 (es)
HU (1) HU9502968D0 (es)
IL (1) IL109254A (es)
NO (1) NO309191B1 (es)
NZ (1) NZ266139A (es)
PL (1) PL311300A1 (es)
SK (1) SK134995A3 (es)
TW (1) TW252978B (es)
WO (1) WO1994025453A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3990972B2 (ja) * 2001-11-20 2007-10-17 有限会社 キック 血管再狭窄防止薬及び該防止薬がコーティングされた血管内埋め込み器具
SE0104274D0 (sv) * 2001-12-17 2001-12-17 Astrazeneca Ab Novel process
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
JP2009523820A (ja) 2006-01-23 2009-06-25 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼの三環系抑制剤
JP2010511632A (ja) 2006-11-30 2010-04-15 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼ活性化タンパク質インヒビターおよび一酸化窒素モジュレーターを含んでいる組成物および治療法
US10793515B2 (en) * 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2015120038A1 (en) 2014-02-04 2015-08-13 Bioscience Pharma Partners, Llc Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system
ME03663B (me) 2015-05-04 2020-07-20 Astrazeneca Ab Derivati rirazola korisni kao inhibitori proteina koji aktivira 5-lipoksigenazu (flap)
JP7041146B2 (ja) 2016-10-28 2022-03-23 アストラゼネカ・アクチエボラーグ （１Ｒ，２Ｒ）－２－［４－（３－メチル－１Ｈ－ピラゾール－５－イル）ベンゾイル］－Ｎ－（４－オキソ－４，５，６，７－テトラヒドロピラゾロ［１，５－ａ］ピラジン－３－イル）シクロヘキサンカルボキサミド

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4794188A (en) * 1982-12-01 1988-12-27 Usv Pharmaceutical Corporation Certain unsymmetrical quinolinyl ethers having anti-inflammatory and anti-allergic activity
US4567184A (en) * 1982-12-01 1986-01-28 Usv Pharmaceutical Corporation Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies
US4625034A (en) * 1985-02-04 1986-11-25 Usv Pharmaceutical Corp. 1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4631287A (en) * 1985-04-16 1986-12-23 Usv Pharmaceutical Corp. Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4725619A (en) * 1985-04-16 1988-02-16 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4728668A (en) * 1985-04-16 1988-03-01 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4868193A (en) * 1986-09-24 1989-09-19 Rorer Pharmaceutical Corporation Styryl tetrazoles and anti-allergic use thereof
GB8926981D0 (en) * 1988-12-23 1990-01-17 Ici Plc Heterocyclic derivatives
US5234950A (en) * 1988-12-23 1993-08-10 Imperial Chemical Industries Plc Tetrahydrofuran derivatives
US5202326A (en) * 1989-02-28 1993-04-13 Imperial Chemical Industries Plc Heterocyclic ethers
IE70521B1 (en) * 1989-02-28 1996-12-11 Zeneca Pharma Sa Heterocycles with inhibitory activity of 5-lipoxygenase
US5236919A (en) * 1989-02-28 1993-08-17 Imperial Chemical Industries Plc Quinoxalinyl derivatives suitable for use in leukotriene mediated disease
US5134148A (en) * 1989-02-28 1992-07-28 Imperial Chemical Industries Plc Heterocycles for use as inhibitors of leukotrienes
IE64358B1 (en) * 1989-07-18 1995-07-26 Ici Plc Diaryl ether heterocycles
GB9018134D0 (en) * 1989-09-29 1990-10-03 Ici Plc Heterocyclic derivatives
US5088927A (en) * 1990-06-18 1992-02-18 Lee Howard G Radio opaque plastics and process of making
AU637500B2 (en) * 1990-06-21 1993-05-27 Zeneca Limited Bicyclic heterocyclic compounds
IE911853A1 (en) * 1990-06-21 1992-01-01 Ici Plc Heterocyclene derivatives
GB9113137D0 (en) * 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
US5272173A (en) * 1990-11-28 1993-12-21 Imperial Chemical Industries Plc 5-lipoxygenase inhibitors
IE913866A1 (en) * 1990-11-28 1992-06-03 Ici Plc Aryl derivatives
EP0501578A1 (en) * 1991-02-28 1992-09-02 Merck Frosst Canada Inc. Pyranylphenyl hydroxyalkylnaphthoic acids as inhibitors of leukotriene biosynthesis
EP0501579A1 (en) * 1991-02-28 1992-09-02 Merck Frosst Canada Inc. Naphthalene lactones as inhibitors of leukotriene biosynthesis
US5308852A (en) * 1992-06-29 1994-05-03 Merck Frosst Canada, Inc. Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis

Also Published As

Publication number Publication date
AP9400632A0 (en) 1995-10-07
GB9408001D0 (en) 1994-06-15
FI955165A (fi) 1995-10-27
IL109254A (en) 1999-03-12
AU681886B2 (en) 1997-09-11
KR100358464B1 (ko) 2003-02-05
JP3553127B2 (ja) 2004-08-11
US5478842A (en) 1995-12-26
FI20020270A (fi) 2002-02-11
FI955165A0 (fi) 1995-10-27
ATE163417T1 (de) 1998-03-15
HU9502968D0 (en) 1995-12-28
EP0623614B1 (en) 1998-02-25
DE69408593D1 (de) 1998-04-02
DK0623614T3 (da) 1998-09-28
AU6721294A (en) 1994-11-21
JPH0770114A (ja) 1995-03-14
HK1004777A1 (en) 1998-12-04
CZ280695A3 (en) 1996-01-17
WO1994025453A1 (en) 1994-11-10
ES2112483T3 (es) 1998-04-01
US5512594A (en) 1996-04-30
IL109254A0 (en) 1994-07-31
NO954321L (no) 1995-10-27
DE69408593T2 (de) 1998-07-16
NO309191B1 (no) 2000-12-27
CA2121199A1 (en) 1994-10-30
CN1121715A (zh) 1996-05-01
EP0623614A1 (en) 1994-11-09
NO954321D0 (no) 1995-10-27
CN1052002C (zh) 2000-05-03
PL311300A1 (en) 1996-02-05
TW252978B (en) 1995-08-01
SK134995A3 (en) 1996-07-03
CA2121199C (en) 2001-08-07
NZ266139A (en) 1997-08-22

Similar Documents

Publication Publication Date Title
US5217978A (en) Substituted-optionally hydrogenated isoquinoline compounds, pharmaceutical compositions and pharmaceutical method of use
EP0462813B1 (en) Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase
US5240941A (en) Thioxo quinoline compounds, composition and method of use
FI109123B (fi) Analogiamenetelmä 5-lipoksigenaasi-inhibiittoreina käyttökelpoisten 4-aryyli-4-hydroksi-tetrahydropyraanien ja 3-aryyli-3-hydroksi-tetrahydrofuraanien valmistamiseksi
US5420298A (en) Pyrrolidine derivatives
US5232930A (en) 2-heteroaryl-substituted benzodioxoic having 5-lipoxygenase inhibitory activity
WO1995030668A1 (en) Cyclic ether derivatives and pharmaceutical composition containing them
HU211245A9 (hu) Éterszármazékok Az átmeneti oltalom az 1-9., 11., 13., 14., 16. és 18. igénypontokra vonatkozik.
WO1994027999A1 (en) Bicyclic ether derivatives and their use as 5-lipoxygenase inhibitors
WO1995004055A1 (en) Thiazole derivatives as lipoxygenase inhibitors
US5478843A (en) Thiazole derivatives
EP0581464A1 (en) Ester derivatives and pharmaceutical compositions containing them
EP0636624A1 (en) Thiazole derivatives as lipoxygenase inhibitors